Durham, NC's Clinverse has put together a $9.1 million C round, raising cash to support its technology for managing costs in clinical trials.
Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A.
Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.
German contract researcher Evotec posted 9% growth in the first half of 2014, executing on its plan to serve as both CRO and proprietary developer in a hybrid approach to R&D.
Repeated regulatory woes for SCM Pharma have left the U.K. contract manufacturer unable to afford its necessary upgrades, forcing Shire, its largest customer, to step in and take over.
Contract developer Almac has earmarked £54 million ($90 million) to expand in its native Northern Ireland, planning to add 348 jobs over 5 years.
WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
Cubist Pharmaceuticals is recalling 100 lots of its banner antibiotic Cubicin after problems with a contract manufacturer, its third such issue in 12 months.
CRO Venn Life Sciences is spreading its reach around Europe through M&A, buying up a French outsourcer to bolster its abilities in data management.
CRO giant Icon continued its steady progress with another double-digit quarter of sales growth, piling up revenue with hopes of clearing $1.5 billion this year.
Charles River Laboratories is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.
Parexel International posted an 11.8% revenue increase in its just-concluded fiscal year, posting record sales and forecasting another banner year.
Belgian medical device CRO Genae has landed in London, giving the fast-growing company a presence in the U.K. as it stretches its reach across Europe.
Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.
Columbia Laboratories has struck a deal with CRO XenoGesis to team up on preclinical research, pooling their resources to offer tandem early-phase services.
Covance posted a strong revenue performance in the second quarter thanks to better-than-expected results from its early-stage development segment, but the CRO is inching back its full-year expectations to account for some outgoing assets.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.
Catalent came through with the biggest life sciences IPO of what's shaping up to be a record year, pulling in $871.3 million in a blockbuster Wall Street debut.
Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.